Cynapsus Therapeutic (CYNAF) 1.0456 $CYNAF
Cynapsus Therapeutics Announces CAD$21 Million Private Placement
Business Wire - Tue Mar 31, 9:26AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced the completion of a private placement (the "Offering"
of 22,039,472 common shares of the Company (the "Common Shares" for gross proceeds of CAD$20,981,579.
CTH.TO: 1.34 (-0.05)
Cynapsus Therapeutics Reports 2014 Annual Results
Business Wire - Tue Mar 17, 4:56PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced financial results for the year ended December 31, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 1.34 (-0.05)
Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18
Business Wire - Mon Mar 16, 5:00AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, announced that it will host an Analyst and Investor Breakfast featuring presentations by executive management and a clinical key opinion leader on Wednesday, March 18, 2015 at 7:30 a.m. in New York City.
CTH.TO: 1.34 (-0.05)
Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
Business Wire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 1.56 (-0.01), NPSP: 45.97 (+0.01), BMY: 64.64 (+1.18), CTH.TO: 1.34 (-0.05)
Cynapsus Therapeutics to start Phase 3 trial for Parkinson's drug in Q2
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 4:08PM CDT
Cynapsus Therapeutics Provides Clinical and Regulatory Update for APL-130277 for the Acute Rescue of OFF Motor Symptoms of Parkinson's Disease
Business Wire - Wed Mar 11, 3:10PM CDT
--Received Final Minutes From End-of-Phase 2 Meeting with U.S. FDA
CTH.TO: 1.34 (-0.05)
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.94 (+0.80), ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25), XNPT: 7.60 (+0.17), IPXL: 50.68 (-0.43), ABBV: 62.00 (+1.68), TEVA: 66.37 (-0.77), SNY: 52.35 (+0.48), PRTA: 36.91 (+0.52)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 50.68 (-0.43), ADMS: 17.94 (+0.80), ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25)
Cynapsus Therapeutics Inc. to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
Business Wire - Thu Jan 15, 3:05PM CST
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1.
CTH.TO: 1.34 (-0.05)
Medical Marijuana Goes To Market: Daniel Pearlstein Of M Partners
Life Sciences Report - at Seeking Alpha - Thu Jan 08, 10:42AM CST
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this...
MNK: 129.09 (+1.29), AUPH: 4.17 (-0.06), HZNP: 28.48 (+1.16), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 42.71 (+0.77), LPCN: 6.84 (+0.01), EPRS: 8.41 (-0.04), DEPO: 24.72 (+0.26), ASPX: 100.58 (+0.10), BCLI: 4.63 (+0.31), CUR: 1.94 (+0.07)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 50.68 (-0.43), ADMS: 17.94 (+0.80), TEVA: 66.37 (-0.77), ACOR: 34.46 (+0.61), PRTA: 36.91 (+0.52), NDRM: 13.93 (-0.25)
Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange's Senior Equity Market
Business Wire - Tue Nov 25, 3:10PM CST
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company's common shares will continue to trade under the symbol "CTH," with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX.
Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease?
Michael Hagan - Seeking Alpha - Tue Nov 25, 7:41AM CST
In the past several weeks, there has been an increase in stories appearing on companies that are involved in Parkinson's disease research. Acorda's (NASDAQ: ACOR ) buyout of Civitas Therapeutics, NeuroDerm's (NASDAQ: NDRM ) (IPO) and the...
ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25)
Cynapsus up on Phase 2 data
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 12:16PM CST
Cynapsus Therapeutics Announces Positive Top-Line Results from CTH-105 Phase 2 Study of APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Business Wire - Wed Nov 19, 5:00AM CST
--Conference call begins at 8:00 a.m. Eastern time today
Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2014
Business Wire - Tue Nov 18, 3:40PM CST
--Conference call to present results to be held at 8:00 a.m. Eastern time
Cynapsus Therapeutics Reports Third Quarter 2014 Financial Results and Recent Developments
Marketwired - Tue Nov 11, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the on-demand rescue of OFF motor symptoms of Parkinson's disease, today announced financial results for the three and nine months ended September 30, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
Acorda Therapeutics Hitting Its Stride As Company Momentum Accelerates
Michael Hagan - at Seeking Alpha - Sat Nov 01, 7:52AM CDT
ACOR: 34.46 (+0.61)
Cynapsus Therapeutics Announces CAD$21 Million Private Placement
Business Wire - Tue Mar 31, 9:26AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced the completion of a private placement (the "Offering"
of 22,039,472 common shares of the Company (the "Common Shares" for gross proceeds of CAD$20,981,579. CTH.TO: 1.34 (-0.05)
Cynapsus Therapeutics Reports 2014 Annual Results
Business Wire - Tue Mar 17, 4:56PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced financial results for the year ended December 31, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 1.34 (-0.05)
Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18
Business Wire - Mon Mar 16, 5:00AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, announced that it will host an Analyst and Investor Breakfast featuring presentations by executive management and a clinical key opinion leader on Wednesday, March 18, 2015 at 7:30 a.m. in New York City.
CTH.TO: 1.34 (-0.05)
Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
Business Wire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 1.56 (-0.01), NPSP: 45.97 (+0.01), BMY: 64.64 (+1.18), CTH.TO: 1.34 (-0.05)
Cynapsus Therapeutics to start Phase 3 trial for Parkinson's drug in Q2
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 4:08PM CDT
Cynapsus Therapeutics Provides Clinical and Regulatory Update for APL-130277 for the Acute Rescue of OFF Motor Symptoms of Parkinson's Disease
Business Wire - Wed Mar 11, 3:10PM CDT
--Received Final Minutes From End-of-Phase 2 Meeting with U.S. FDA
CTH.TO: 1.34 (-0.05)
New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST
ADMS: 17.94 (+0.80), ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25), XNPT: 7.60 (+0.17), IPXL: 50.68 (-0.43), ABBV: 62.00 (+1.68), TEVA: 66.37 (-0.77), SNY: 52.35 (+0.48), PRTA: 36.91 (+0.52)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 50.68 (-0.43), ADMS: 17.94 (+0.80), ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25)
Cynapsus Therapeutics Inc. to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
Business Wire - Thu Jan 15, 3:05PM CST
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1.
CTH.TO: 1.34 (-0.05)
Medical Marijuana Goes To Market: Daniel Pearlstein Of M Partners
Life Sciences Report - at Seeking Alpha - Thu Jan 08, 10:42AM CST
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this...
MNK: 129.09 (+1.29), AUPH: 4.17 (-0.06), HZNP: 28.48 (+1.16), GSK: 48.23 (+0.51), BMY: 64.64 (+1.18)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 42.71 (+0.77), LPCN: 6.84 (+0.01), EPRS: 8.41 (-0.04), DEPO: 24.72 (+0.26), ASPX: 100.58 (+0.10), BCLI: 4.63 (+0.31), CUR: 1.94 (+0.07)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 50.68 (-0.43), ADMS: 17.94 (+0.80), TEVA: 66.37 (-0.77), ACOR: 34.46 (+0.61), PRTA: 36.91 (+0.52), NDRM: 13.93 (-0.25)
Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange's Senior Equity Market
Business Wire - Tue Nov 25, 3:10PM CST
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company's common shares will continue to trade under the symbol "CTH," with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX.
Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease?
Michael Hagan - Seeking Alpha - Tue Nov 25, 7:41AM CST
In the past several weeks, there has been an increase in stories appearing on companies that are involved in Parkinson's disease research. Acorda's (NASDAQ: ACOR ) buyout of Civitas Therapeutics, NeuroDerm's (NASDAQ: NDRM ) (IPO) and the...
ACOR: 34.46 (+0.61), NDRM: 13.93 (-0.25)
Cynapsus up on Phase 2 data
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 12:16PM CST
Cynapsus Therapeutics Announces Positive Top-Line Results from CTH-105 Phase 2 Study of APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Business Wire - Wed Nov 19, 5:00AM CST
--Conference call begins at 8:00 a.m. Eastern time today
Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2014
Business Wire - Tue Nov 18, 3:40PM CST
--Conference call to present results to be held at 8:00 a.m. Eastern time
Cynapsus Therapeutics Reports Third Quarter 2014 Financial Results and Recent Developments
Marketwired - Tue Nov 11, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the on-demand rescue of OFF motor symptoms of Parkinson's disease, today announced financial results for the three and nine months ended September 30, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
Acorda Therapeutics Hitting Its Stride As Company Momentum Accelerates
Michael Hagan - at Seeking Alpha - Sat Nov 01, 7:52AM CDT
ACOR: 34.46 (+0.61)
